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Interleukin 17 (IL-17) is a newly identified cytokine that has a homolog in herpesvirus saimiri. We inserted murine IL-17 into
vaccinia virus to study the role of IL-17 in viral infection. Vaccinia virus expressing IL-17 (vv-IL17) and its parental control virus
(vv-pRB) grew to similar titers in vitro; however, vv-IL17 was more virulent in mice with a threefold lower LD50 than for vv-pRB,
and mean time to death of 2.8 days versus 4.5 days. Mice infected with vv-IL17 had higher titers of virus in the ovaries (P 
0.02) and showed a decrease in NK cell cytotoxicity (P  0.02) on day 3 after infection. No significant difference was found
in CTL activity. In addition, a significant decrease in IgG2a (P  0.01) and increases in IgG1, IgG3, and IgA (P  0.03) vaccinia
virus-specific antibody titers were observed in mice infected with vv-IL17 versus vv-pRB, suggesting a Th-2-like response toINTRODUCTION
Herpesvirus saimiri (HVS) encodes a homolog of IL-17
(Rouvier et al., 1993; Yao et al., 1995), referred to as viral
IL-17 (vIL-17). HVS is a T cell tropic gammaherpesvirus
which causes asymptomatic infection in its natural host,
the squirrel monkey (Fleckenstein and Desrosiers, 1982).
However, HVS induces T cell lymphomas in cottontop
tamarins and transforms human T cells in vitro (Biesinger
et al., 1992; Fickenscher and Fleckenstein, 1998). The
persistence of HVS in monkeys suggests that it, as with
many other viruses, has evolved a strategy to evade the
host immune system by “capturing” host immunomodu-
latory proteins (Spriggs, 1994; Tortorella et al., 2000).
Several gammaherpesviruses encode homologs of cyto-
kine genes and their receptors. For example, Epstein–
Barr virus (EBV) encodes an IL-10 homolog (Moore et al.,
1990), Kaposi’s sarcoma-associated herpesvirus (KSHV)
encodes an IL-6 homolog (Moore et al., 1996), and HVS
and KSHV encode IL-8 receptor homologs. These ho-
mologs may reduce the effectiveness of the antiviral
immune response during acute infection until latency is
established. IL-6 and IL-10 regulate the production or
function of Th1 cytokines and cellular immune re-
sponses. BCRF1, the EBV homolog of IL-10, inhibits ac-
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production of IFN-, which has direct antiviral activity.
BCRF1 also reduces production of IL-2 and IL-12, which
help to activate cytotoxic T lymphocytes (CTL) and nat-
ural killer (NK) cells. Similarly, KSHV has an IL-6 homolog
(K2). IL-6 can promote B cell proliferation and antibody
production and suppresses NK cell activity and lympho-
kine-activated killer (LAK) cell activity (Lotz, 1995; Scheid
et al., 1994).
HVS encodes a functional homolog of IL-17; however,
while the functions of the EBV and KSHV immunomodu-
latory proteins have been studied intensively and hypoth-
eses have been formulated as to why the viruses have
captured these proteins, the function of IL-17 in viral
pathogenesis is unclear. vIL-17 is expressed during the
lytic cycle of HVS infection, but not during latency
(Knappe et al., 1998). Recent data indicate that HVS viral
IL-17 is dispensable for infection, replication, and onco-
genesis of HVS in cottontop tamarins (Knappe et al.,
1998).
In vitro studies have shown that despite only 58%
amino acid identity between the murine and viral ho-
mologs of IL-17, both species of IL-17 can induce activa-
tion of NF-B, induce production of IL-6, and enhance the
proliferative response of T cells (Yao et al., 1995). Human
IL-17 induces the differentiation of CD34 human pro-
genitor cells into neutrophils (Fossiez et al., 1996, 1998)
and promotes maturation of bone marrow derived
CD11c dendritic cells in vitro (Antonysamy et al., 1999).
In addition, human IL-17 upregulates the proinflamma-
tory cytokines IL-1 and TNF-, functions usually attrib-
uted to Th1-type cytokines (Jovanovic et al., 1998). How-infection. These data indicate that IL-17 modulates the im
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ever, the multiple functions ascribed to IL-17 in vitro may
not reflect its true role in vivo.mune r
us; vac
In order to study the role of IL-17 during virus infection
in a small animal model, we inserted IL-17 into vaccinia
virus and infected mice with the recombinant virus. In-
sertion of most cytokines into vaccinia virus (e.g., IL-1,
IL-2, IFN-, and IL-12) reduces viral virulence by boosting
the cellular immune response (Ramshaw et al., 1992).
However, using this model system, we found that IL-17
increased the virulence of vaccinia virus in vivo and
inhibited NK cell activity on day 3. In addition, antibody
isotypes generated in response to infection with recom-
binant vaccinia virus expressing IL-17 showed a sub-
stantial decrease in IgG2a, suggestive of a Th2-like re-
sponse.
RESULTS
Cells infected with vv-IL17 secrete functional IL-17
Production of IL-17 by cells infected with vv-IL17 was
determined by immunoprecipitation and ELISA. IL-17 is
secreted as a mixture of homodimeric glycosylated and
nonglycosylated polypeptides (Fossiez et al., 1998; Yao et
al., 1995). Under reducing conditions, both the 21-kDa
glycosylated and 15-kDa nonglycosylated forms of mu-
rine IL-17 were detectable in cell lysates and superna-
tants of vv-IL17 infected HeLa cells (Fig. 1). IL-17 was not
detected in vv-pRB infected samples. In addition, high
levels of IL-17 (1000 pg/ml) were detected by ELISA in
supernatants of vv-IL17 infected BSC-1 cells, but not
vv-pRB infected cells.
IL-17 has been shown to induce production of IL-6 and
IL-8 by fibroblasts (Yao et al., 1995). To determine
whether IL-17 secreted from vv-IL17 infected cells was
biologically active, filtered virus infected cell culture su-
pernatants were added to murine NIH 3T3 fibroblasts.
Secretion of IL-6 was measured by ELISA and was found
to be induced by vv-IL17 culture supernatant but not by
vv-pRB or mock infected supernatants. Addition of fil-
tered supernatant from BSC-1 cells infected with vv-IL-17
to murine 3T3 cells resulted in production of 11.5 ng/ml of
murine IL-6.
vv-pRB and vv-IL17 grow to similar titers in vitro
The growth of vv-pRB and vv-IL17 recombinant vac-
cinia viruses was compared in BSC-1 cells. Cells were
infected with the two vaccinia viruses, and virus was
harvested and titered at various time points after infec-
tion in BSC-1 cells. The mean titers from three indepen-
dent experiments are shown in Table 1. No significant
difference was observed in the peak titers of vv-pRB or
vv-IL17 from 4 to 48 h after infection.
IL-17 increases the virulence of vaccinia virus in mice
Female BALB/c mice were infected intraperitoneally
with 1  105 to 5  109 PFU of vaccinia virus. All mice
infected with 1.6  108 PFU of vv-IL17 died by day 5 after
infection, while 60% of mice infected with the same dose
of vv-pRB survived greater than 20 days (Fig. 2). All mock
infected animals survived. The mean time to death for
vv-IL17 infected mice was 2.8 days. Of the animals that
died who received vv-pRB, the mean time to death was
4.5 days. Using different doses of virus in three indepen-
dent experiments, the 50% lethal dose for vv-IL17 was
one-third that of vv-pRB (5.4  107 PFU and 1.8  108
PFU, respectively). Therefore, expression of IL-17 in-
creased the virulence of vaccinia virus.
While the two recombinant vaccinia viruses grew to
similar titers in vitro, mice infected with a sublethal dose
FIG. 1. Production of IL-17 by cells infected with vv-IL17. Immunopre-
cipitation of HeLa cell lysates (L) and culture supernatants (S) after
infection with vv-pRB (lanes 1 and 2) or vv-IL17 (lanes 3 and 4).
Glycosylated (21 kDa) and nonglycosylated (15 kDa) forms of IL-17 are
present. Numbers on the left indicate molecular weights of proteins in
kilodaltons.
TABLE 1
Titers of vv-pRB and vv-IL17 in BSC-1 Cells
Inoculum
Hours postinfection (PFU/ml)
2 4 8 17 24 48
vv-pRB 1.1 103  0.4 6.0 102  3.1 6.7 102  1.8 2.7 104  0.2 2.7 105  0.2 2.4 107  1.0
vv-IL17 0.5 103  0.1 2.8 102  1.7 8.7 102  5.7 1.6 104  0.9 1.9 105  0.7 1.0 107  0.5
P value Rank Sum 0.05 0.38 0.66 0.51 0.51 0.28
Note. Each value represents the mean titer  SE from three independent experiments.
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of vv-IL17 (2.5  106 PFU/mouse) had significantly in-
creased virus titers in their ovaries during the first 3 days
after infection compared with vv-pRB infected mice (Ta-
ble 2). Thereafter, the titer of both viruses was similar in
the ovaries. Furthermore, weight loss also occurred dur-
ing the first 3 days after infection. After this time, the mice
recovered from infection and regained weight (data not
shown).
Several features of infection with vv-IL17 suggested
that IL-17 might be inhibiting the early immune response
to vaccinia. Most of the deaths in animals receiving
vv-IL17 occurred within the first 5 days after infection,
and the elevated virus titers in the ovaries and weight
loss in vv-IL17 infected animals occurred during the first
3 days of infection. Since the initial response to virus
infection includes activation of NK cells (Biron et al.,
1999), we analyzed this response in mice receiving vac-
cinia expressing IL-17 or the control virus.
Mice infected with vv-IL17 have decreased NK cell
activity
Mice were infected with a sublethal dose of vv-pRB or
vv-IL17 or uninfected cell lysates. NK cell cytotoxicity was
measured on days 2 through 7 after infection; however,
lysis of Yac-1 target cells above background levels (5%)
was consistently detectable only on day 3. NK cell activ-
ity on day 3 was significantly decreased at all effector:
target (E:T) ratios tested in mice infected with vv-IL17
compared to vv-pRB (P  0.03; Fig. 3A). At an E:T ratio
of 200:1, mean specific lysis of YAC-1 target cells by total
splenocytes was reduced from 23% in mice infected with
vv-pRB to 13% in mice infected with vv-IL17. The number
of lytic units per spleen required to achieve 15% lysis
was significantly lower for vv-IL17 infected animals
(68.7  10.5) than for vv-pRB infected animals (203.9 
64.2; P  0.02; Fig. 3B). While NK cell cytotoxicity was
diminished on day 3 after infection, flow cytometric anal-
ysis of total splenocytes using a pan NK cell antibody
(DX5) showed no difference in total NK cell numbers in
mice infected with vv-IL17 compared with vv-pRB. On day
3 after infection (Fig. 3C), mice infected with vv-IL17 had
5.7  0.4% CD3DX5 NK cells compared with 5.4 
0.3% in vv-pRB infected mice (P  0.6). No significant
differences were observed on days 2 to 7 in cells ex-
pressing Ly49C, another NK cell marker, which is a killer
inhibitory receptor. For example, on day 3 after infection
(Fig. 3C), mice infected with vv-IL17 had 2.1  0.2%
Ly49C NK cells compared with 2.1  0.1% for vv-pRB
(P  0.6).
Vaccinia virus-specific CTL activity was assayed on
days 2 to 7 after infection, but was detectable above
background levels only on days 5 to 7, and activity
peaked on day 6. In contrast to the decrease in NK cell
activity, no difference in CTL lysis was observed after
infection of mice with vv-IL17 compared to vv-pRB on
days 5 to 7 after infection. For example, on day 6 after
infection the level of CTL lysis was similar for animals
infected with vv-IL17 and vv-pRB at all E:T ratios tested
(Fig. 4). Nonspecific lysis of uninfected P815 targets by
splenocytes from all animals and lysis of vaccinia-in-
fected targets by splenocytes from mock infected ani-
mals were below 5%. No significant difference was found
in total splenic CD8 T cell numbers on days 2 to 7 after
infection of mice with vv-IL17 compared with vv-RB.
Infection with vv-IL17 results in decreased vaccinia
virus-specific IgG2a
Since other gammaherpesviruses such as EBV and
KSHV encode cytokines (IL-10 and IL-6, respectively) that
FIG. 2. Survival curve of BALB/c mice infected intraperitoneally with
1.6  108 PFU of vv-pRB (}), vv-IL17 (), or uninfected cell lysate ().
TABLE 2
Titers of vv-pRB and vv-IL17 in Ovaries of BALB/c Mice
Inoculum
Days postinfection (PFU/ml)
1 2 3 5 6
vv-pRB 8.4 102  6.4 4.8 106  0.7 4.2 106  6.4 9.3 109  3.5 1.1 109  3.0
vv-IL17 29.2 103  0.8 21.4 106  2.7 38.8 106  10.8 6.9 109  2.0 1.6 109  2.4
P value Rank Sum 0.05 0.01 0.03 0.63 0.27
Note. Each value represents mean titer  SE per group of five mice.
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have Th2 activities, we postulated that the murine ho-
molog of a cytokine encoded by HVS might also elicit
Th2 effects. Therefore we measured subclasses of vac-
cinia-specific immunoglobulins in mice infected with vv-
IL17 or vv-pRB to determine if they were indicative of a
Th1 or Th2 response. Levels of vaccinia-specific IgG1,
IgG3, and IgA were significantly elevated 14 days after
infection of mice with vv-IL17, compared with animals
receiving vv-pRB (P  0.01, 0.01, and 0.03 respec-
tively; Fig. 5). Conversely, the level of vaccinia-specific
IgG2a was decreased in animals inoculated with vv-IL17
compared with vv-pRB (P  0.01). Virus-specific IgE
was not detectable. Since IgG1, IgG3, and IgA isotypes
are indicative of a Th2-type response, while IgG2a is a
Th1-type antibody, these data suggest that IL-17 more
closely resembles a Th2 cytokine.
DISCUSSION
We have shown that IL-17 increases the virulence of
vaccinia virus infection and modulates the immune re-
sponse to virus infection in mice. Survival of mice in-
fected with vv-IL17 is significantly reduced compared to
mice infected with vv-pRB. The increased virus titers in
the ovaries of mice infected with vv-IL17 from days 1 to 4
after infection and rapid mean time to death at lethal
doses of vv-IL17 (2.8 days) indicate an effect on the early
immune response to the virus. A decrease in NK cell
cytotoxicity was noted in animals infected with vv-IL17 on
day 3, without an apparent change in NK cell numbers
compared to mice infected with the control virus. NK cell
activity is important for recovery from vaccinia virus and
herpesvirus infections. NK cell proliferation has been
reported early after vaccinia virus infection (Dokun et al.,
FIG. 3.NKcell activity of splenocytes fromBALB/cmice infectedwith 2.5
106 PFU of vv-pRB (}), vv-IL17 (), or uninfected cell lysate (). (A) NK cell
activity on day 3 after infection. Percentage specific lysis of Yac-1 target cells
by total splenocytes from infected mice. Each point represents the mean per
group (mean of triplicates per animal). Error bars indicate standard error. (B)
Lytic units per spleen calculated for 15% NK cell lysis per individual animal.
Each point represents an individual mouse, and means per group are shown
by the central horizontal bar. (C) Percentage of splenic NK cells 3 days after
infection with vv-pRB (black bars) or vv-IL17 (white bars). Each bar represents
the mean per group of five individual mice. Error bars indicate standard error.
FIG. 4. CTL activity of splenocytes from BALB/c mice 6 days after
infection with 2.5  106 PFU of vv-pRB (}), vv-IL17 (), or uninfected
cell lysate (). Percentage specific lysis of vaccinia infected P815
target cells by total splenocytes from mice (solid lines). Uninfected P815
cells were used as controls for nonspecific lysis (dotted lines). Each
point represents the mean per group (mean of triplicates per animal).
Error bars indicate standard error.
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2001), and depletion of NK cells in mice results in in-
creased vaccinia virus replication (Bukowski et al., 1983).
In addition, low NK cell activity increases the severity of
infection with several herpesviruses including herpes
simplex virus, EBV, varicella-zoster virus, and human
cytomegalovirus (CMV) (Biron et al., 1989; Habu et al.,
1984; Joncas et al., 1989; Quinnan et al., 1982; Sullivan et
al., 1980). While NK cells are important for recovery from
vaccinia virus infection, a recent study indicates that 
T cells have an important role in the innate immune
response to vaccinia virus infection (Selin et al., 2001).
Several cytokines inhibit NK cell activity, including IL-6
(Scheid et al., 1994) and IL-10 (Kurilla et al., 1993). Mice
infected with vaccinia virus expressing IL-10 have de-
creased NK cell activity on day 3 and decreased CTL
activity on days 6 and 7 after infection (Kurilla et al.,
1993). Our data suggest that IL-17 also inhibits NK cell
cytotoxicity on day 3 after vaccinia virus infection. EBV
(Moore et al., 1990) and CMV (Kotenko et al., 2000)
encode homologs of IL-10 and KSHV expresses an IL-6
homolog (Moore et al., 1996). Thus IL-17, which is
present in the HVS genome, may be the third cytokine
encoded by a herpesvirus that inhibits NK cell activity.
Interestingly, IL-17 induces production of prostaglandin
E2 (PGE2), IL-6, and IL-10 (reviewed in Patera and Cohen,
2001), and each of these molecules can inhibit NK cell
activity (Bankhurst, 1982; Brunda et al., 1980; Kurilla et al.,
1993; Scheid et al., 1994).
While it is possible that IL-17 directly caused disease
in mice, rather than enhancing the virulence of vaccinia
virus, we think that the former is unlikely for several
reasons. First, there have been no reports of toxic effects
of IL-17 in the literature, either by direct intraperitoneal
injection of 0.5 g recombinant murine IL-17 into mice
(Witowski et al., 2000) or when murine IL-17 was deliv-
ered by recombinant adenovirus vectors (Schwarzen-
berger et al., 1998, 2001). On the contrary, adenovirus
expressing IL-17 was “well tolerated and without appar-
ent morbidity” (Schwarzenberger et al., 1998) and sur-
vival of lethally irradiated mice was increased 85% by
FIG. 5. Vaccinia virus-specific antibody isotype distribution. IgA, IgG1, IgG3, and IgG2a vaccinia-specific antibody titers were determined from sera
of BALB/c mice 14 days after infection with 106 PFU vv-pRB or vv-IL17 or uninfected cell lysates (mock). Each point represents the end-point titer for
an individual mouse. Mean titers per group are indicated by horizontal bars. This experiment was performed three times and a representative result
is shown.
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adenovirus expressing mIL-17 (Schwarzenberger et al.,
2001). Second, in our study, postmortem examination of
mice dying from lethal doses of vv-pRB or vv-IL17
showed no apparent differences; therefore, the deaths
were likely to be linked to increased virus infection rather
than to toxicity of IL-17. Third, serum levels of IL-17 were
not detectable by ELISA in vv-IL17 infected mice on days
1 to 7 after infection.
The capture of IL-17 by HVS might have several ad-
vantages for the virus. First, IL-17 might increase the
number of available T cells as targets for virus replica-
tion. Yao et al. (1995) showed that addition of viral (or
murine) IL-17 to mouse splenic T cells in vitro enhanced
phytohemagglutitin induced proliferative responses and
Schwarzenberger et al. (1998, 2001) showed a twofold
increase in peripheral blood lymphocytes in animals
infected with adenovirus expressing murine IL-17. Sec-
ond, HVS encodes an IL-8 receptor, and the ability of
IL-17 to up-regulate IL-8 (Fossiez et al., 1996) could pro-
vide autocrine stimulation for virus infected cells. Third,
IL-17 might shift the host response from a Th1- to a
Th2-type immune response and promote a more favor-
able environment for acute infection. The capture of IL-10
by CMV and EBV and of IL-6 by KSHV suggests that this
strategy is common among the herpesviruses. Mice in-
fected with vaccinia virus expressing IL-17 showed a
Th2-like profile with elevated levels of vaccinia virus-
specific IgG1, IgG3, and IgA and a substantial decrease
in IgG2a. However, IL-17 has not been definitively clas-
sified as either a Th1 or a Th2 cytokine since expression
of IL-17 has been detected in Th0, Th1, and/or Th2 T cell
clones in vitro (Aarvak et al., 1999; Albanesi et al., 2000;
Chabaud et al., 2001). At present it is unclear which, if
any, of these effects of IL-17 contributes to the pathogen-
esis of HVS infection. While deletion of IL-17 from HVS
had no effect on the ability of the virus to cause lympho-
mas in cottontop tamarins (Knappe et al., 1998), studies
of a deletion mutant in the natural host (squirrel mon-
keys) may help to establish the true role of this cytokine
in HVS infection.
MATERIALS AND METHODS
Construction of recombinant vaccinia viruses
CV-1 cells were infected with vaccinia virus (vRB12) in
which 93% of the vp37 gene has been replaced by the
Escherichia coli gpt gene and then transfected with ei-
ther plasmid pRB21 or pRB21-IL17. Plasmid pRB21 con-
tains the vp37 gene followed by a synthetic vaccinia virus
early/late promoter, a multiple cloning site, and stop
codons (Blasco and Moss, 1995). Plasmid pRB21-IL17
contains the murine IL17 gene (Yao et al., 1996) inserted
into the SalI–NotI site of the multiple cloning site of
pRB21. The first five amino acids of the IL-17 signal
sequence were replaced with the murine IL-7 leader
sequence to enhance expression of murine IL-17 (Yao et
al., 1995). Recombinant vaccinia viruses were screened
by PCR for the absence or presence of the IL-17 se-
quence and plaque purified. Virus with vp37 from the
pRB21 plasmid or with both vp37 and IL-17 was desig-
nated vv-pRB or vv-IL17, respectively.
In vitro growth of vv-pRB and vv-IL17
BSC-1 cell monolayers were infected with vv-pRB or
vv-IL17 at an m.o.i. of 0.01. Cells were harvested at 2, 4,
8, 17, 24, and 48 h after infection and viral titers were
determined by plating serial dilutions of cell lysates on
BSC-1 cells. Plaques were counted on day 2 and virus
titers were calculated.
Detection of IL-17
HeLa cells were infected with vv-pRB or vv-IL17 and
labeled with [35S]methionine. Cell lysates were prepared,
and lysates and supernatants from infected cells were
incubated with a soluble IL-17 receptor–Fc fusion protein
(Yao et al., 1995) followed by protein A–Sepharose. Im-
mune complexes were fractionated on SDS–polyacryl-
amide gels and autoradiography was performed. IL-17
was also detected in cell culture supernatants from vv-
IL17 infected cells using an anti-murine IL-17 ELISA kit
according to the manufacturer’s instructions (R&D Sys-
tems). In addition, IL-17 was detected by its ability to
induce IL-6 in NIH 3T3 cells. HeLa cells were infected
with vv-pRB or vv-IL17 or mock infected with HeLa cell
lysate. Culture supernatant was harvested 2 days later
and filtered twice through 0.22-m Millipore filters to
remove virus. Tenfold dilutions of supernatants were
added to NIH 3T3 fibroblast monolayers overnight. 3T3
cell culture supernatants were harvested, filtered, and
assayed for IL-6 production using an anti-murine IL-6
ELISA kit (Endogen).
Animal experiments
Groups of five BALB/c female mice ages 6–8 weeks
(Harlan) were inoculated intraperitoneally with vv-pRB or
vv-IL17 or uninfected cell lysate in PBS. Doses ranged
from 105 to 5  109 PFU per mouse in half-log incre-
ments. Mice were monitored for signs of morbidity and
mortality and the 50% lethal dose (LD50) was calculated
(Lennette, 1964).
In vivo virus replication was assayed by infection of
mice with a sublethal dose of vv-pRB or vv-IL17 (2.5 106
PFU/mouse). Body weights were recorded as an indica-
tor of illness. Animals were euthanized on days 1 to 6
and ovaries were obtained. Virus titers were determined
by homogenizing both ovaries in 1 ml of PBS and plating
serial dilutions of the homogenate on BSC-1 cells.
Plaques were counted on day 2 and virus titers calcu-
lated as plaque-forming units per milliliter per mouse.
The mean virus titer per group of five mice was calcu-
lated and plotted for each time point.
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NK and CTL killing assays
Groups of five mice were inoculated intraperitoneally
with uninfected cell lysates or a sublethal dose of vv-pRB
or vv-IL17 (2.5  106 PFU). Spleens were harvested 1 to
7 days after infection for NK cell and CTL assays. Single-
cell suspensions were prepared after red cell lysis with
ACK lysing buffer (Quality Biological Inc.) and used in
standard chromium release assays. To determine NK
cell activity, Yac-1 target cells were labeled with 51Cr and
incubated for 4 h with splenocytes from individual mice
at E:T ratios ranging from 25:1 to 200:1 in triplicate wells.
To determine CTL activity, P815 target cells were infected
with parental vaccinia virus vv-pRB and then labeled with
51Cr. Uninfected P815 cells were also labeled and used
as controls for nonspecific lysis. Target cells were then
incubated for 6 h with splenocytes from individual mice
in triplicate at E:T ratios ranging from 25:1 to 200:1.
Supernatants were collected and 51Cr release was mea-
sured. Spontaneous release was determined as counts
per minute of 51Cr released by target cells incubated with
medium alone. Maximum release was the amount of 51Cr
released after treatment of targets with 5% NP-40. The
percentage specific lysis of target cells was calculated
as (cpm experimental release  spontaneous release/
maximum release  spontaneous release)  100. The
mean percentage specific lysis per group of five mice
(mean of triplicates per individual animal) was calcu-
lated. Lytic units per spleen were calculated as total
number of splenocytes/number of effector cells required
for 15% specific lysis per individual animal (Kurilla et al.,
1993).
Flow cytometry
Groups of five mice were inoculated intraperitoneally
with 2.5  106 PFU of vv-pRB or vv-IL17. Splenocytes were
stained with fluorescein isothiocyanate-conjugated anti-
CD3 and phycoerythrin-conjugated antibodies against DX5,
Ly49C, or CD8 (PharMingen). Cell populations were deter-
mined by flow cytometric analysis using FACScan II and
CellQuest software.
Anti-vaccinia virus antibody isotyping
Groups of five mice were infected intraperitoneally
with a sublethal dose of vv-pRB or vv-IL17 (2.5  106
PFU/mouse) or mock infected with uninfected cell lysate.
Sera were obtained 14 days postinfection and anti-vac-
cinia virus antibody titers and isotypes were determined
by ELISA. Microtiter plates were coated with 106 PFU/
well of vv-pRB vaccinia virus in 0.05 M carbonate buffer
(pH 9.6) overnight at 4°C. After being blocked with 2%
milk in PBS, serial dilutions of sera were incubated with
the vaccinia virus coated plates overnight at 37°C. The
isotype of bound antibody was determined using alkaline
phosphatase-conjugated anti-mouse IgG1, IgG2a, IgG3,
and IgA antibodies (Organon Teknika and Zymed) or
biotin conjugated anti-mouse IgE antibody (Caltag) and
streptavidin–horseradish peroxidase (HRP; Zymed). End-
point titers were obtained when OD 410 nm (alkaline
phosphatase) or OD 450 nm (HRP) readings of hyperim-
mune sera were greater than twice those of sera ob-
tained from animals before vaccinia virus infection. End-
point titers for each mouse were plotted and mean titers
per group of five mice were calculated.
Statistical analysis
Data were expressed as the mean per group  stan-
dard error. Statistical analysis was done using JMP ver-
sion 3.2.2 software. Probability (P) values were deter-
mined for all assays by the Wilcoxon–Kruskal Wallis Test
(Rank Sums).
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